Avaleht › Burkitti lümfoom › Ohio

Burkitti lümfoom kliinilised uuringud osariigis Ohio

17 uuringut haiguse Burkitti lümfoom jaoks otsivad osalejaid osariigis Ohio.

Linnad osariigis Ohio

Ametlik uuringutekst (inglise keeles)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
ja veel 3

VärbamineFaas 2

366 Days – 46 Years · Kõik sood · Uuendatud 2. okt 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Case Western Reserve University, Cleveland
Cleveland Clinic Foundation, Cleveland
ja veel 2

VärbamineFaas 3

Vanused 18–39 · Kõik sood · Uuendatud 2. okt 2026 · NCT03150693

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Cincinnati Children's Hospital Medical Center, Cincinnati

VärbamineVaatlusuuring

Vanused 0–38 · Kõik sood · Uuendatud 1. okt 2026 · NCT06131801

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Ohio State University Comprehensive Cancer Center, Columbus
University of Cincinnati Cancer Center-West Chester, West Chester

VärbamineFaas 2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. sept 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
ja veel 2

VärbamineFaas 2

365 Days · Kõik sood · Uuendatud 25. sept 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

University of Cincinnati Medical Center, Cincinnati

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 21. sept 2026 · NCT07648264

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati

VärbamineFaas 3

Vanused 1 ja vanemad · Kõik sood · Uuendatud 17. sept 2026 · NCT07223021

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
ja veel 3

VärbamineFaas 2

Vanused 1–30 · Kõik sood · Uuendatud 1. sept 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
ja veel 4

VärbamineFaas 3

365 Days – 25 Years · Kõik sood · Uuendatud 25. aug 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Cincinnati Children's Hospital Medical Center, Cincinnati

VärbamineFaas 2

Vanused 7–25 · Kõik sood · Uuendatud 19. aug 2026 · NCT05082519

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

The Ohio State University Wexner Medical Center, Columbus

VärbamineFaas 1/2

Vanused 13–90 · Kõik sood · Uuendatud 6. aug 2026 · NCT06533579

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Nationwide Children's Hospital, Columbus
Ohio State University Comprehensive Cancer Center, Columbus

VärbamineFaas 1

Vanused 2 ja vanemad · Kõik sood · Uuendatud 29. mai 2026 · NCT05418088

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Cleveland Clinic Foundation, Cleveland

VärbamineFaas 2

Vanused 18–54 · Kõik sood · Uuendatud 17. märts 2026 · NCT06918431

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Cincinnati Children's Hospital Medical Center, Cincinnati

VärbamineFaas 1

Vanused 1–39 · Kõik sood · Uuendatud 18. veebr 2026 · NCT06863259

Study of SGR-1505 in Mature B-Cell Neoplasms

Gabrail Cancer & Research Center, Canton
The Ohio State University - The James Cancer Hospital, Columbus

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 13. veebr 2026 · NCT05544019

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Cleveland Clinic, Cleveland

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 5. nov 2025 · NCT04260022

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

University of Cincinnati, Cincinnati

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 15. nov 2024 · NCT06034275

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.